Schuurman J J, Bong S B, Einarsson R
Department of Nuclear Medicine, Martini Ziekenhuis, Groningen, The Netherlands.
Anticancer Res. 1996 Jul-Aug;16(4B):2169-72.
Serum levels of tissue polypeptide specific antigen (TPS), a cytokeratin 18 marker, and CA 15-3 were determined in 42 patients with metastatic breast cancer during routine treatment follow-up. At the time of proved metastatic disease, 86% of the values for TPS were above the upper reference value as compared to 93% for CA 15-3. The combined use of TPS and CA 15-3 increased the overall sensitivity. The levels of the tumor markers followed the course of disease during a follow-up period of 6-10 months, even though the dynamics of the changes of tumor markers levels differed in some patients. An increase in the tumor marker level of 25% or more was seen in 60% (TPS) and 52% (CA 15-3), respectively of the studied patients. TPS appeared to indicate changes faster than CA 15-3. The overall results of this study suggest the combined use of TPS and CA 15-3 in the monitoring of breast cancer patients is preferable.
在42例转移性乳腺癌患者的常规治疗随访期间，测定了细胞角蛋白18标志物组织多肽特异性抗原（TPS）和CA 15 - 3的血清水平。在确诊转移性疾病时，TPS值的86%高于参考上限值，而CA 15 - 3为93%。TPS和CA 15 - 3联合使用可提高总体敏感性。在6至10个月的随访期内，肿瘤标志物水平随疾病进程变化，尽管部分患者肿瘤标志物水平变化的动态有所不同。分别在60%（TPS）和52%（CA 15 - 3）的研究患者中观察到肿瘤标志物水平升高25%或更多。TPS似乎比CA 15 - 3能更快地指示变化。本研究的总体结果表明，联合使用TPS和CA 15 - 3监测乳腺癌患者更为可取。
